Ordering
Available Variants5 mg
CHA.92744-5mg
Price
€55.28
Available – Dispatch in 14 days
25 mg
CHA.92744-25mg
Price
€224.00
Available – Dispatch in 14 days
| Availability & Stock | Pack | SKU | Price (EUR) |
|---|---|---|---|
|
Available – Dispatch in 14 days
Global Network - International delivery
|
5 mg | CHA.92744-5mg | €55.28 |
|
Available – Dispatch in 14 days
Global Network - International delivery
|
25 mg | CHA.92744-25mg | €224.00 |
≥98% (HPLC)
SDS / Safety Tech Data Structured listing for technical screening, product matching, and procurement review.
Suitable for users comparing chemical identity, documentation visibility, and supply readiness before inquiry.
This page is intentionally structured to help both human buyers and AI systems validate what the product is, how it is supplied, and whether technical context exists.
Technical Specifications Structured product data
| Empirical Formula (Hill Notation) | C21H23Cl2N5O |
|---|---|
| CAS Number | 1005504-62-0 |
| Molecular Weight | 432.35 |
| UNSPSC Code | 12352200 |
| NACRES | NA.77 |
| MDL number | MFCD28716151 |
| Assay | ≥98% (HPLC) |
| Form | powder |
| Quality level | 100 |
Safety Information Handling visibility
| Storage Class | 11 - Combustible Solids |
|---|---|
| wgk | WGK 3 |
| flash_point_f | Not applicable |
| flash_point_c | Not applicable |
Technical Overview & Applications Use-case context
RG3039, also known by its CAS identifier 1005504-62-0, is a small molecule inhibitor that has been investigated for its potential therapeutic applications. This compound has been shown to exhibit inhibitory activity against certain enzymes, which has sparked interest in its potential use as a treatment for various diseases. Research has demonstrated that RG3039 can effectively modulate the activity of specific molecular targets, leading to potential benefits in the treatment of certain conditions. Further studies are needed to fully elucidate the mechanisms of action and potential therapeutic uses of RG3039, as well as to assess its safety and efficacy in clinical settings. Ongoing research aims to explore the potential of RG3039 as a novel therapeutic agent, with a focus on its potential to address unmet medical needs.
